|Huadong Medicine||Huadong Medicine (stock code: 000963) was founded in 1993, and is headquartered in Hangzhou, Zhejiang. It was listed on the Shenzhen Stock Exchange in December 1999. The company’s business covers pharmaceutical industry, pharmaceutical business and medical aesthetics industry.It has developed into a large-scale comprehensive pharmaceutical company integrating research and development, production and distribution. Huadong Medicine is the 17th largest pharmaceutical company in China. In 2020, the company’s annual sales revenue of 5 billion USD. Key therapeutic areas include oncology, immunology, diabetes and nephrology.|
|Haisco Pharma||Haisco Pharmaceutical Group, founded in 2000, has business in new drug development, manufacturing and sales .Haisco is dedicated to developing and supplying the best medicine to protect the health and wellbeing of the patients we serve, and aspires to become a mostly trusted leading enterprise in medical and healthcare industry. Haisco has 15 NCEs in the pipeline in the field of Anesthesia, Pain and Oncology, and 3 proprietary technology platfroms. Haisco was listed on the Shenzhen Stock Exchange in 2012. In 2017, Haisco established its R&D centers in the United States. The sales reached over 500 million dollars in 2020.|
|Yiling Pharma||Yiling Pharmaceutical was established on June 16th, 1992. Originally it was only a small clinic called “Shijiazhuang Development Zone Medical Research Institute”. After years of fast development, it has grown into a listed company in Shenzhen Stock Exchange with 7 billion Yuan of net asset and 30 billion Yuan of market value. As a company with more than 10,000 employees, Yiling Pharmaceutical has made a protruding contribution to social and economic development. Due to the comprehensive strength, Yiling Pharmaceutical has won many honorary titles such as National Key Hi-tech Enterprise, Top 20 Listed Pharmaceutical Company, etc. Yiling Trademark has won the title of “China Famous Brand”.|
|Jingxin Pharmaceutical||Founded in 1990, the company is a listed pharmaceutical company integrating R&D, production and sales.|
The company is a national key high-tech enterprise, with a national enterprise technology center, post-doctoral research station, provincial key enterprise research institute, and Shanghai Research Institute in Shanghai Zhangjiang Hi-Tech Park.
It has passed the new version of GMP certification, the solid preparation production line took the lead in 2006 by passing the German GMP certification. In 2018, it also passed the FDA on-site certification.
“Top 100 Chinese Pharmaceutical Industry”
|Fosun Orinove||Fosun Orinove, with its US subsidiary Orinove located in Thousand Oaks, CA, is an innovative research and development pharmaceutical company led by a team of scientists with many years of experience in US major pharmaceutical and biotechnology companies. Fosun Orinove is funded by Fosun Pharma, a healthcare conglomerate company in China. Orinove’s main product ORIN1001 is an IRE1a inhibitor, an oral, small molecule first-in-class clinical-stage drug with a novel target, enzyme type and mechanism of action. In the ongoing two phase I oncology clinical trials conducted both in US and China, it has demonstrated a good safety and pharmacodynamics profile with emerging sign of efficacy for solid tumors. ORIN1001 targets a common mechanism of tumor cell survival, therefore it has a platform potential for many oncology indications. IRE1a is also a critical enzyme that is involved in multiple pathways that leading to idiosyncratic pulmonary fibrosis (IPF), its inhibition is theorized to be able control this detrimental disease. In order to fully seize the opportunity that ORIN1001 exhibits as a potential blockbuster product, and further secure its current leading development position in this field, Orinove decides to expand the original planned investment to accelerate the current clinical trials, and start multiple phase II clinical trials in 2022.|
|Luye Pharma Group||Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting central nervous system (CNS), oncology, cardiovascular and other therapeutic areas. Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities.|
| Kelun-Biotech Pharmaceutical||Kelun-Biotech, a holding subsidiary of Kelun Industry Group, founded in 2016, focusing on research and development, production and sales of innovative biotechnology drugs and innovative chemical small molecule drugs.|